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We determined whether the approved myelofibrosis drug ruxolitinib (Jakafi®), an inhibitor 
of Janus kinases 1/2 (JAK1 and JAK2), could be repurposed as an anti-cancer agent 
for solid tumors. Ruxolitinib synergistically interacted with dual ERBB1/2/4 inhibitors 
to kill breast as well as lung, ovarian and brain cancer cells. Knock down of JAK1/2 
or of ERBB1/2/3/4 recapitulated on-target drug effects. The combination of (ruxoli-
tinib + ERBB1/2/4 inhibitor) rapidly inactivated AKT, mTORC1, mTORC2, STAT3, and 
STAT5, and activated eIF2α. In parallel, the drug combination reduced expression of 
MCL-1, BCL-XL, HSP90, HSP70, and GRP78, and increased expression of Beclin1. 
Activated forms of STAT3, AKT, or mTOR prevented the drug-induced decline in BCL-XL, 
MCL-1, HSP90, and HSP70 levels. Over-expression of chaperones maintained AKT/
mTOR activity in the presence of drugs and protected tumor cells from the drug combi-
nation. Expression of dominant negative eIF2α S51A prevented the increase in Beclin1 
expression and protected tumor cells from the drug combination. Loss of mTOR activity 
was associated with increased ATG13 S318 phosphorylation and with autophagosome 
formation. Autophagosomes initially co-localized with mitochondria and subsequently 
with lysosomes. Knock down of Beclin1 suppressed: drug-induced mitophagy; the 
activation of the toxic BH3 domain proteins BAX and BAK; and tumor cell killing. Knock 
down of apoptosis-inducing factor (AIF) protected tumor cells from the drug combina-
tion, whereas blockade of caspase 9 signaling did not. The drug combination released 
AIF into the cytosol and increased nuclear AIF: eIF3A co-localization. A 4-day transient 
exposure of orthotopic tumors to (ruxolitinib + afatinib) profoundly reduced mammary 
tumor growth over the following 35 days. Re-grown tumors exhibited high levels of BAD 
S112 phosphorylation and activation of ERK1/2 and NFκB. Our data demonstrate that 
mitophagy is an essential component of (ruxolitinib + ERBB inhibitor) lethality and that 
this drug combination should be explored in a phase I trial in solid tumor patients.
Keywords: ruxolitinib, JaK1/2, afatinib, erBB1, mitophagy, chaperone, aiF
Abbreviations: ca, constitutively active; cCasp3, cleaved caspase 3; CMV, empty vector plasmid or virus; dn, dominant negative; 
ER, endoplasmic reticulum; ERK, extracellular regulated kinase; IP, immunoprecipitation; JAK, Janus Kinase; MAPK, mitogen-
activated protein kinase; MEK, mitogen-activated extracellular regulated kinase; mTOR, mammalian target of rapamycin; 
PI3K, phosphatidyl inositol 3 kinase; PTEN, phosphatase and tensin homolog on chromosome ten; ROS, reactive oxygen 
species; SCR, scrambled; si, small interfering; STAT, signal transducers and activators of transcription; VEH, vehicle.
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inTrODUcTiOn
Immune cell activation in general and particularly during rheu-
matoid arthritis progression requires signaling by Janus kinases 
(JAK1, JAK2, JAK3). Thus pharmaceutical companies, attacking 
these kinases as drugable targets, have developed several FDA-
approved agents in the hope of reducing the negative sequelae 
of arthritis and of semi-tumorigenic myelo-proliferative disor-
ders: Jakafi and Xeljanz, respectively (1–4). Jakafi (ruxolitinib) 
inhibits JAK1 and JAK2, whereas Xeljanz (tofacitinib) inhibits 
JAK3 and to a lesser extent JAK1. In the field of cancer research 
and therapy ruxolitinib has been used, logically based on its 
immune cell actions, in the treatment of myelo-proliferative 
disorders, myelogenous neoplasms, and auto-immune diseases, 
such as psoriasis (5). The Janus kinases phosphorylate signal 
transducers and activators of transcription (STAT) transcrip-
tion factors on tyrosine resulting in factor dimerization and 
nuclear localization, and eventually activation of various target 
genes (6–10). Thus, mutated active forms of Janus kinases or the 
actions of mutated activated growth factor receptors through 
autocrine loops cause constitutive activation of the STAT1/
STAT3/STAT5 transcription factors that promote the malig-
nant phenotype. Growth factor receptors, such as ERBB1, and 
c-MET also have been shown to phosphorylate STAT factors 
on tyrosine residues thereby promoting dimerization/activation 
(11, 12). Cyto-protective genes activated by STAT transcription 
factors are many and include those coding for anti-apoptotic 
genes, such as MCL-1, BCL-XL, BCL-2, survivin, HSP90, and 
HSP70; proliferation regulatory genes, such as Cyclin D1, 
Cyclin B, c-Jun, and c-Fos; and angiogenesis promoting genes, 
such as HIF1α, and growth factors, such as IL-6, FGF, EGF, and 
VEGF (13–20).
It is well known that in the majority of tumor cell isolates 
across all malignancies, i.e., cells that are generally not addicted 
to any one specific single driving oncogene, that in order to 
kill the tumor cell effectively in  vitro and in  vivo requires the 
combinatorial use of two or more modulators of signal trans-
duction pathways. For example, published studies from this 
laboratory combining (MEK1/2 inhibitors + CHK1 inhibitors); 
(sorafenib/regorafenib  +  PI3K/AKT inhibitors); (MMF and 
XRT/Temozolomide); and (HSP90 inhibitors + MEK1/2 inhibi-
tors) are good illustrations of this dual pathway inhibition to kill 
concept (21–29).
More recent studies from this laboratory have extended the 
dual pathway inhibition killing concept by the use of multiplex 
antibody array assays on drug-treated tumors that permit 
simultaneous analyses of plasma cytokine levels and the activ-
ity status of multiple signal transduction parameters in tumors/
tumor cells surviving the dual pathway inhibition treatment. 
For example, in 2015, we published that the drugs sorafenib/
regorafenib interacted with phosphodiesterase 5 inhibitors, 
such as sildenafil (Viagra) and tadalafil (Cialis) in a synergistic 
fashion to kill tumor cells in vitro and in vivo (28). Based on 
multiplex assays of plasma and tumor material from the rodent 
tumor studies contained within this paper, we discovered that 
these drug combination treatments caused a compensatory 
activation of ERBB1/2/4-PI3K-AKT in the liver and colorectal 
tumor cells surviving the (sorafenib/regorafenib +  sildenafil) 
drug treatments. Nota bene: tumors from two different GI tis-
sues exhibited very similar compensatory/evolutionary survival 
signaling responses. And, the combination of an ERBB1/2/4 
inhibitor or a PI3K inhibitor or an AKT inhibitor with (sorafenib/
regorafenib  +  sildenafil) was then shown to profoundly 
enhanced tumor cell killing in vitro. New phase I and phase II 
trials have opened at VCU combining (regorafenib + sildenafil) 
and (sorafenib  +  sildenafil  +  valproate) for all solid tumor 
patients and for glioblastoma (GBM) patients, respectively 
(NCT02466802; NCT02337426).
Very recently, we have shown that a major novel component 
of the biology of the drugs OSU-03012 (AR12), sorafenib and 
pazopanib, but to a much lesser extent regorafenib, afatinib or 
ruxolitinib, is the actual inhibition of protein chaperone ATPase 
activities and, hence, reducing the ability of chaperones to inter-
act with each other and with their many client proteins (30–33). 
The present studies were performed to determine whether the 
myeloid-proliferative disorder drug ruxolitinib could be repur-
posed for use as an anti-cancer therapy for solid tumors. The 
plasma C max for ruxolitinib in patients undergoing standard of 
care therapy is ~136 μM with >95% of the drug protein bound, 
although significantly higher doses of the drug were safely 
administered to patients during drug development clinical evalu-
ations. Thus, in vitro studies in the present manuscript generally 
use ruxolitinib-phosphate at a concentration of 2.5 μM or less 




Lapatinib tosylate, Afatinib, Neratinib, Vandetanib, and 
Ruxolitinib-phosphate were purchased from Selleckchem 
(Houston, TX, USA). Trypsin–EDTA, DMEM, RPMI, penicillin-
streptomycin were purchased from GIBCOBRL (GIBCOBRL Life 
Technologies, Grand Island, NY, USA). Mono-methyl fumarate 
was from Sigma (St. Louis, MO, USA). Cells were purchased from 
the ATCC and were not further validated beyond that claimed by 
ATCC. Cells were re-purchased every ~6 months. Primary human 
GBM cells, developed by Dr. C.D. James when at the Mayo Clinic 
(Rochester, MN, USA) have been described previously. ADOR 
non-small cell lung cancer cells are personal a donation from the 
patient to the Dent laboratory. De novo cisplatin resistant “Spiky” 
ovarian cancer cells, a patient-derived explant (PDX) model, 
were kindly provided by Dr. Karen Paz (Champions Oncology, 
NJ, USA). The plasmid to express GRP78 was kindly provided 
to the Dent laboratory by Dr. A.S. Lee (University of Southern 
California Los Angeles, CA, USA). The plasmids to express 
HSP27, eIF2α S51A, kinase-inactive PERK, and all others listed 
in this manuscript were purchased from Addgene (Cambridge, 
MA, USA). Commercially available validated short hairpin RNA 
molecules to knock down RNA/protein levels were from Qiagen 
(Valencia, CA, USA) or were supplied by collaborators. Reagents 
and performance of experimental procedures were described in 
Refs. (30–33).
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Methods
Culture and In Vitro Exposure of Cells to Drugs
All cell lines were cultured at 37°C [5% (v/v CO2)] in vitro using 
RPMI supplemented with dialyzed 5% (v/v) fetal calf serum and 
10% (v/v) Non-essential amino acids. In vitro drug treatments 
were from 100 mM stock solutions of each drug and the maximal 
concentration of Vehicle (DMSO) in media was 0.02% (v/v). Cells 
were not cultured in reduced serum media during any study in 
this manuscript.
Transfection of Cells with siRNA or with Plasmids
For Plasmids
Cells were plated and 24  h after plating, transfected. Plasmids 
expressing a specific mRNA (or siRNA) or appropriate vector 
control plasmid DNA was diluted in 50 μl serum-free and anti-
biotic-free medium (one portion for each sample). Concurrently, 
2 μl Lipofectamine 2000 (Invitrogen) was diluted into 50 μl of 
serum-free and antibiotic-free medium (one portion for each 
sample). Diluted DNA was added to the diluted Lipofectamine 
2000 for each sample and incubated at room temperature for 
30 min. This mixture was added to each well/dish of cells con-
taining 200 μl serum-free and antibiotic-free medium for a total 
volume of 300 μl, and the cells were incubated for 4 h at 37°C. An 
equal volume of 2× medium was then added to each well. Cells 
were incubated for 24 h, then treated with drugs.
Transfection for siRNA
Cells from a fresh culture growing in log phase as described 
above, and 24 h after plating transfected. Prior to transfection, 
the medium was aspirated and serum-free medium was added 
to each plate. For transfection, 10 nM of the annealed siRNA, the 
positive sense control double-stranded siRNA targeting GAPDH 
or the negative control (a “scrambled” sequence with no signifi-
cant homology to any known gene sequences from mouse, rat or 
human cell lines) were used. Ten nanomolar siRNA (scrambled or 
experimental) was diluted in serum-free media. Four-microliter 
Hiperfect (Qiagen) was added to this mixture and the solution 
was mixed by pipetting up and down several times. This solution 
was incubated at room temp for 10 min, then added drop-wise 
to each dish. The medium in each dish was swirled gently to mix, 
then incubated at 37°C for 2 h. Serum-containing medium was 
added to each plate, and cells were incubated at 37°C for 24 h 
before then treated with drugs (0–24  h). Additional immuno-
fluorescence/live–dead analyses were performed at the indicated 
time points.
Multiplex Assays
A MAGPIX multiplex instrument with associated software was 
purchased from Bio-Rad. The following Bio-Plex assay plates were 
used in our assays of mouse plasma for human cytokines: Bio-Plex 
Pro Human Cytokine Group I 4-plex (Y500023JM2); Human 
CYTO STD GRP II 23-PLEX (171D60001); Human CYTO HGF 
set (171B6008M); Human CYTO SDF-1a set (171B6019M); Pro 
Human Cancer 2 18-plex (171AC600M); BP Pro TGF-B 3-PLEX 
(171W4001M). Mouse plasma was assayed according to the 
instructions provided by Bio-Rad to assess human cytokine levels 
derived from the BT474 tumors. The following Bio-Plex assay 
plates were used in our assays for tumor cell signal transduction 
proteins: Bio-Plex Bio-Plex Pro Phospho-protein magnetic 8-plex 
Assay (LQ00004IXUYDC4); Bio-Plex Pro Phospho-protein 
magnetic 15-plex Assay (LQ000064Q3MJ1). Tumor lysates were 
assayed according to the instructions provided by Bio-Rad to 
assess human signaling changes derived from the BT474 tumors.
Detection of Cell Viability, Protein Expression, and 
Protein Phosphorylation by Immuno-Fluorescence 
Using a Hermes WiScan Machine
The vast majority of the in vitro analyses in these manuscripts, 
and the present set of studies, used a novel approach to detect 
gross changes in protein expression and protein phosphorylation: 
a Hermes WiScan wide field microscope (http://www.idea-bio.
com/). Set at 10× magnification, in a 96-well plate format, gross 
assessments of protein expression/phosphorylation can be made, 
i.e., an “in-cell western,” using unbiased pre-programed electronic 
data acquisition, much as has previously been performed for the 
last 45  years using SDS-PAGE and western immunoblotting. 
However, the Hermes system permits 96 samples to be measured 
simultaneously in up to three fluorescent color channels in con-
trast to our Odyssey infra-red machine for western blotting that 
has two channels and is limited to ~20 samples per gel. Using the 
Hermes system has an additional benefit: while western immuno-
blotting often “loses” proteins that denature and form detergent 
insoluble complexes that do not electrophorese down the gel, 
using the Hermes system all cellular proteins have the potential 
of being detected due to its in situ non-denatured methodology 
(30–33). The machine also has in-built software to assess changes 
in fluorescent intensity thereby making the quantitation of signal 
intensities straight-forward. Cells (4 × 103) are plated into each 
well of a 96-well plate, and cells permitted to attach and grow 
for the next 18 h. Based on the experiment, after 18 h, cells are 
then either genetically manipulated, or are treated with drugs. 
For genetic manipulation, cells are transfected with plasmids or 
siRNA molecules and incubated for an additional 24 h. Cells are 
treated with vehicle control or with drugs at the indicated final 
concentrations, alone or in combination. Cells are then isolated 
for processing at various times following drug exposure. The 
96-well plate is centrifuged/cyto-spun to associate dead cells (for 
live–dead assays) with the base of each well. For live–dead assays, 
after centrifugation, the media is removed and cells treated with 
live–dead reagent (Thermo Fisher Scientific, Waltham, MA, 
USA) and, after 10 min, this is removed and the cells in each well 
are visualized in the Hermes instrument at 10× magnification. 
Green cells =  viable; yellow/red cells =  dying/dead. The num-
bers of viable and dead cells were counted manually from three 
images taken from each well combined with data from another 
two wells of separately treated cells (i.e., the data are the mean 
cell dead from nine data points from three separate exposures). 
For immuno-fluorescence studies, after centrifugation, the media 
is removed and cells are fixed in place and permeabilized using 
ice cold PBS containing 0.4% paraformaldehyde and 0.5% Triton 
X-100. After 30 min, the cells are washed three times with ice cold 
PBS and cells are pre-blocked with rat serum for 3 h. Cells are 
then incubated with a primary antibody to detect the expression/
phosphorylation of a protein (usually at 1:100 dilution from a 
4Tavallai et al. Ruxolitinib and Cancer Therapy
Frontiers in Oncology | www.frontiersin.org June 2016 | Volume 6 | Article 142
commercial vendor) overnight at 37°C. Cells are washed three 
times with PBS followed by application of the secondary antibody 
containing an associated fluorescent red or green chemical tag. 
After 3  h of incubation, the antibody is removed and the cells 
washed again. The cells are visualized at either 10× or 60× in 
the Hermes machine for imaging assessments. All immunofluo-
rescent images for each individual protein/phospho-protein are 
taken using the identical machine settings so that the levels of 
signal in each image can be directly compared to the level of 
signal in the cells treated with drugs. Similarly, for presentation, 
the enhancement of image brightness/contrast using PhotoShop 
CS6 is simultaneously performed for each individual set of pro-
tein/phospho-protein to permit direct comparison of the image 
intensity between treatments.
For SDS-PAGE and immunoblotting, cells were plated at 
5 × 105 cells/cm2 and treated with drugs at the indicated con-
centrations and after the indicated time of treatment, lysed in 
whole-cell lysis buffer (0.5 M Tris-HCl, pH 6.8, 2% SDS, 10% 
glycerol, 1% β-mercaptoethanol, 0.02% bromophenol blue), and 
the samples were boiled for 30  min. The boiled samples were 
loaded onto 10–14% SDS-PAGE and electrophoresis was run 
overnight (10–100 μg/lane based on the gel size). Proteins were 
electrophoretically transferred onto 0.22-μm nitrocellulose, 
and immunoblotted with various primary antibodies against 
different proteins. Antibodies used include: HSP90 (E289) 
(Cell Signaling); HSP90 (#2928) (Abcam); HSP90 (ab195575) 
Abcam; HSP90 3G3 (13495) (Abcam); GRP78 (50b12) (31772) 
(Cell Signaling); GRP78 (ab191023) Abcam; GRP78 (ab103336) 
Abcam; GRP78 (N-20) (sc-1050) Santa Cruz; HSP27 (G31) 
(2402P) Cell Signaling); HSP27 (EP1724Y) (ab62339) Abcam; 
HSP27 (H-77) (sc-9012) Santa Cruz; HSP27 (LS-C31836) 
Lifespan science Corp. Other antibodies were as used in prior 
studies by the laboratory.
Animal Studies
Animal studies were performed according to Federal Law and 
under an approved Virginia Commonwealth University IACUC 
protocol (#AD10001065). Athymic nude mice (~20  g) were 
injected with 1 ×  107 BT474 cells into their fourth mammary 
fat pad (10 animals per treatment group; 4 groups; a total of 
40 mice ± SEM). Tumors were permitted to form for 7 days with 
tumors at that time exhibiting a mean volume of ~15 mm3. This is 
the equivalent of a 3.7 cm3 massed tumor in the breast of a 50 kg 
adult female patient. Athymic mice were treated by oral gavage 
once every day for 4 days as indicated in the Figure and Figure 
Legend with vehicle (Cremophore); with ruxolitinib (50 mg/kg 
BID) on days 1–4; with MMF on days 1–4 (50 mg/kg); and with 
afatinib (25  mg/kg QD) on days 1–4. After cessation of drug 
treatment, tumors are again callipered, and tumor volume was 
assessed up to 35 days later.
Data Analysis
Comparison of the effects of various treatments was performed 
using one way analysis of variance and a two-tailed Student’s 
t-test. Statistical examination of in  vivo animal survival data 
utilized log-rank statistical analyses between the different 
treatment groups. Differences with a p-value of <0.05 were 
considered statistically significant. Experiments shown are the 
means of multiple individual points from multiple experiments 
(±SEM).
resUlTs
Our earliest studies determined whether the ERBB1/2/4 inhibi-
tor lapatinib interacted with the JAK1/2 inhibitor ruxolitinib to 
kill breast cancer cells. In a dose-dependent fashion, ruxolitinib 
interacted with lapatinib to kill within 24  h: SUM149; BT549; 
HCC38; and BT474 mammary tumor cells (Figure 1A). Of note, 
SUM149, BT549, and HCC38 cells are considered to be “triple 
negative” and do not over-express ERBB2; BT549 and HCC38 
cells lack PTEN function. Similar tumor cell killing data to that 
using lapatinib as shown in Figure  1 were obtained using the 
second- and third-generation ERBB1/2/4 inhibitors afatinib, ner-
atinib, sapatinib, tagrisso, and poziotinib (Figure 1B, not shown). 
Of note, the more recently developed second/third-generation 
suicide ERBB receptor inhibitors were more capable of rapidly 
interacting with ruxolitinib and at lower concentrations, than 
was the first-generation inhibitor lapatinib, in terms of tumor 
cell killing. The lethal interaction between ERBB1/2/4 inhibitors 
and ruxolitinib was not only discovered in mammary tumor cells 
but was also found in HCT116 colon, A498 renal and MiaPaca2 
pancreatic and multiple NSCLC cells, including the July 2015 
ERBB3-dependent ADOR isolate (Figure 1C). In multiple fresh 
low passage 2012–2015 PDX isolates of human GBM and medul-
loblastoma (SPAC), lapatinib and ruxolitinib interacted to reduce 
growth and kill tumor cells (Figure 1D). Collectively, these data 
also imply that tumor cells expressing activated RAS proteins 
or lacking the tumor suppressor PTEN are killed by the drug 
combination.
Ruxolitinib and ERBB receptor inhibitors are known to 
modulate the functions and activities of many intracellular 
signal transduction pathways, and we next explored the impact 
our ruxolitinib based drug combination had on cell signaling 
processes. In BT474 cells as judged by western immunoblotting 
lapatinib and ruxolitinib in combination caused prolonged inhi-
bition of the phosphorylation of ERBB1, ERBB2, ERK1/2, AKT, 
mTOR, STAT3, STAT5, and the phosphorylation of p65 NFκB 
(Figure 2A; effects all >50%, p < 0.05). Very similar data were 
obtained in triple-negative SUM149 cells when the changes in 
cell signaling parameters were measured using in situ immuno-
fluorescence on native proteins in a Hermes WiScan machine at 
10× magnification (Figures  2B,C). Assessments of changes in 
cell signaling using multiplex antibody array analyses in a Bio-
Rad MAGPIX machine were also very similar to data generated 
using western blotting and immuno-fluorescence (Figure  3). 
The drug combination, as assessed by immuno-fluorescence, 
by 12  h had reduced the phosphorylation of ERK1/2, AKT 
T308, STAT3, and STAT5 by >75% (p < 0.05 less than vehicle 
control treated). From our multiplex antibody array analyses 
on in  vitro cell lysates, we discovered that the combination of 
(ruxolitinib + lapatinib) did not alter IκB expression or its S32 
S36 phosphorylation but did reduce NFκB p65 S536 phospho-
rylation, and decreased the expression of multiple protective 
and pro-inflammatory cytokines whose expression is regulated 
FigUre 1 | The JaK1/2 inhibitor ruxolitinib interacts with the erBB1/2/4 inhibitor lapatinib to kill breast cancer cell lines that: lack PTen; 
over-express erBB2; and are classified as triple negative. (a) SUM149, BT549, HCC38, and BT474 cells were treated with vehicle control, ruxolitinib-
phosphate (2.5/5.0 μM), lapatinib tosylate (1.0 μM) or the drugs in combination. Twenty-four hours later, cell viability was assessed using a live/dead assay in a 
Hermes WiScan microscope at 10× magnification (n = 3 ± SEM) *p < 0.05 greater than vehicle control. (B) BT474, BT549, SKBR3, and SUM149 cells were treated 
with vehicle control, ruxolitinib-phosphate (2.5 μM), afatinib (1.0 μM), neratinib (1.0 μM), or the drugs in combination as indicated. Twenty-four hours later, cell viability 
was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification (n = 3 ± SEM). (c) HCT116 (colon); A498 (renal); Mia Paca2 
(pancreatic) and multiple NSCLC lines including the July 2015 PDX isolate ADOR; cancer cells were treated with vehicle control, ruxolitinib-phosphate (2.5 μM), 
lapatinib (2.0 μM) or the drugs in combination as indicated. (D) Primary human glioblastoma cells (P1-P7) and a PDX model of recurrent medulloblastoma (SPAC) 
cancer cells were treated with vehicle control, ruxolitinib-phosphate (1.0 μM), lapatinib (1.0 μM) or the drugs in combination as indicated. Twenty-four hours later, cell 
viability under all conditions was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification.
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by NFκB, including CXCL-1, IL-1 beta, IL-8, CCL13, MIF, and 
CCL20. As assessed by both western immunoblotting and by 
immuno-fluorescence, 12 h after exposure, lapatinib as a single 
agent had enhanced mTOR activity that is presumably a form of 
compensatory survival mechanism, an effect that was blocked by 
co-exposure with ruxolitinib.
The autophagy gate-keeper kinase mTOR occurs in two pro-
tein complexes termed mTORC1 and mTORC2. Phosphorylation 
of mTOR at Serine 2448 is a biomarker for mTORC1 activity, 
whereas phosphorylation of mTOR Serine 2481 is a biomarker 
for mTORC2 activity. We discovered that (ruxolitinib + afatinib) 
treatment reduced mTOR phosphorylation at both S2448 and 
S2481 in multiple breast and lung cancer cell lines, including the 
NSCLC PDX isolate ADOR, arguing that our drug combination 
was inactivating both the mTORC1 and mTORC2 signaling 
complexes (Figure  4A). And, in agreement with mTORC2 
complex inactivation, the drug combination reduced AKT S473 
phosphorylation (Figure  3). Finally, we determined whether 
transient exposure to lapatinib and ruxolitinib killed tumor 
cells in a synergistic fashion using median dose effect analyses 
on tumor cell colony formation. Ruxolitinib synergized with 
lapatinib to kill SUM149 mammary tumor cells in transient drug 
exposure colony formation assays, with combination index values 
significantly below 1.0 (Figure 4B).
Next, using molecular tools, we defined which ERBB family 
members in different cell types were responsible for the interac-
tion of ERBB receptor inhibitors and ruxolitinib. SUM149 cells 
were isolated from an inflammatory breast cancer patient whose 
tumor was defined as “triple negative” but which nevertheless in 
our hands expressed detectable basal levels of ERBB1, ERBB2, 
ERBB3, and ERBB4 by immuno-fluorescence of cells fixed in situ 
(Figure 5A). In SUM149 cells combined but not individual knock 
down of ERBB1, ERBB3, and ERBB4 strongly enhanced ruxoli-
tinib toxicity. In BT474 cells, generally defined as a breast cancer 
FigUre 2 | lapatinib and ruxolitinib interact to inactivate aKT, mTOr, sTaT3, sTaT5, and erK1/2 as judged by western blotting. (a) BT474 cells were 
treated with vehicle control, ruxolitinib (1.0 μM), lapatinib (1.0 μM) or the drugs in combination for 6 h and for 12 h. At each time point cells were lysed with RIPA 
buffer and clarified by centrifugation. Ten milligram of protein from each lysate was subjected to SDS-PAGE on 10% gels. Proteins were transferred to 0.2 μm 
nitrocellulose and probed with antibodies generated against the indicated proteins and phospho-proteins. Bands were imaged using a first generation Odyssey 
Infra-Red imager at 300 dpi. (n = 3 ± SEM). (B,c) SUM149 cells were treated with vehicle control, ruxolitinib (1.0 μM), lapatinib (1.0 μM), or the drugs in combination 
for 6 h and for 12 h. At each time point, cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed on native proteins 
to detect the total expression and phosphorylation levels of ERBB1, ERBB2, STAT3, STAT5, ERK1/2, AKT T308, mTOR S2448; NFκB p65 S536, MCL-1, and 
cleaved caspase 3 (cCasp3) (n = 3 ± SEM).
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cell type over-expressing ERBB2, we also detected expression of 
all four ERBB receptor members, and in this cell line combined 
knock down of ERBB1 and ERBB2 was sufficient to enhance 
ruxolitinib toxicity, though this effect was further enhanced by 
the additional knock down of ERBB4 (Figure 5B). GBM12 brain 
cancer cells, a PDX model isolated approximately a decade ago, 
express all ERBB receptors, including a full-length mutated active 
ERBB1, and, as we observed with the mammary SUM149 cells, 
the enhancement of ruxolitinib toxicity in GBM12 cells required 
combined knock down of ERBB1, ERBB3, and ERBB4 (data not 
shown). Ruxolitinib is claimed to be a specific inhibitor of the 
Janus kinases JAK1 and JAK2, but does not block JAK3 or TYK2, 
and we next determined whether knock down of JAK1 and 
JAK2 could account for the effects of ruxolitinib. Knock down 
of both JAK1 and JAK2 enhanced the lethality of lapatinib and 
of afatinib in the BT474 and SUM149 mammary carcinoma cells 
(Figure 5C).
In Figures 1–5, we demonstrated that the activities of ERK1/2, 
AKT, mTOR, STAT3, and NFκB p65 were being decreased 
for at least 12  h by our (ruxolitinib +  ERBB inhibitor) drug 
combination and we next determined the impact of pathway 
inactivation(s) on tumor cell viability. In SUM149 triple-negative 
breast cancer cells, expression of an activated form of STAT3 
or an activated form of AKT strongly inhibited the lethality of 
(ruxolitinib + lapatinib) treatment (Figure 6A). In BT474 cells 
expression of an activated form of STAT3, an activated form of 
MEK1 or an activated form of AKT also inhibited the lethality of 
(ruxolitinib + lapatinib) treatment. The (ruxolitinib + afatinib) 
drug combination rapidly reduced the expression of BCL-XL 
(by >70%, p <  0.05), MCL-1 (by >70%, p <  0.05), TGF-beta 
isoforms (by > 50%, p < 0.05) as well as the total protein levels 
of the chaperones HSP90 and HSP70 as measured using an 
antibody against the COOH-termini of the proteins; effects 
that were partially or fully reversed by expression of activated 
STAT3, activated AKT, or activated MEK1 (Figures 6B and 7A) 
(30). Of additional note, (ruxolitinib + afatinib) treatment also 
induced an endoplasmic reticulum stress response as judged by 
increased eIF2α S51 phosphorylation, and increased Beclin1 
and CHOP expression. Expression of a dominant negative eIF2α 
S51A protein prevented the increases in Beclin1 and CHOP 
expression and partially protected tumor cells from (ruxoli-
tinib + afatinib) exposure (data not shown). These findings are 
very similar to our recent clinically relevant data combining 
(pemetrexed + sorafenib) where the ability of this combination 
FigUre 3 | Multiplex antibody array assays of sUM149 cells treated with ruxolitinib, lapatinib, or the drug combination. SUM149 cells were treated 
with vehicle control, ruxolitinib (1.0 μM), lapatinib (1.0 μM), or the drugs in combination for 4 h, for 8 h, and for 12 h. At each time point, cells were lysed and 
clarified by centrifugation. Clarified tumor cell lysates were then subjected to multiplex assays as described in the section “Methods” to detect the tumor lysate 
levels of the indicated cytokines and phosphorylation status of signal transduction proteins in the tumor using a Bio-Rad MAGPIX multiplex instrument 
(n = 3 ± SEM).
FigUre 4 | The JaK1/2 inhibitor ruxolitinib interacts with the erBB1/2 inhibitor afatinib to reduce the phosphorylation of mTOr at serine 2448  
and serine 2481: inactivation of mTOrc1 and mTOrc2. (a) BT474, ADOR, SUM149, and H1975 cells were treated with vehicle control or [ruxolitinib 
(2 μM) + afatinib (2 μM)] for 6 h. After 6 h, cells were fixed in place and immuno-fluorescence was performed to detect at 60× magnification or at 10× as indicated, 
the phosphorylation status of mTOR S2448 and mTOR S2481. (B) Triple-negative SUM149 cells were plated (250–1,000) cells per well of a six well plate and 12 h 
after plating were treated with vehicle, ruxolitinib (0.25–1.5 μM; 0.5–2.5 μM), lapatinib (0.25–1.5 μM), or in combination at a constant ratio for 24 h, as indicated. 
The media was removed, cells were washed with drug-free media, and the cells cultured for another 10 days in drug-free media. Cell colonies were fixed, stained 
and groups of cells >50 were counted as colonies. The combination index (CI) for synergy was calculated using the Calcusyn for Windows program using the  
Cho and Tallalay Method (n = 2; 12 individual wells per data point ± SEM). A combination index of <0.70 indicates a strong level of tumor-killing synergy between 
the drugs.
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FigUre 5 | ruxolitinib synergizes with knock down of erBB1/erBB3/erBB4 to kill sUM149 triple-negative breast cancer cells. (a) SUM149 cells were 
transfected with a scrambled siRNA (siSCR) or with siRNA molecules to knock down the expression of ERBB1, ERBB2, ERBB3, ERBB4, either alone, or in 
combinations, as indicated in the figure. Twenty-four hours after transfection, cells were treated with vehicle control or ruxolitinib (2.5–10.0 μM), as indicated. 
Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification (n = 3 ± SEM) *p < 0.05 greater 
than vehicle control. (B) BT474 cells were transfected with a scrambled siRNA (siSCR) or with siRNA molecules to knock down the expression of ERBB1, ERBB2, 
ERBB3, ERBB4, either alone, or in combinations, as indicated in the figure. Twenty-four hours after transfection, cells were treated with vehicle control or ruxolitinib 
(2.5–10.0 μM), as indicated. Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification 
(n = 3 ± SEM) *p < 0.05 greater than vehicle control. (c) SUM149 and BT474 cells were transfected with a scrambled siRNA or with siRNA molecules to knock down 
expression of JAK1 and JAK2. Twenty-four hours after transfection, cells were treated with vehicle control, lapatinib (1 μM), or afatinib (0.5 μM). Twenty-four hours, 
later cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification (n = 3 ± SEM) *p < 0.05 greater than vehicle control.
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to cause an ER stress response and increase Beclin1 levels was 
key to tumor cell killing (32).
We then performed animal studies to define whether our 
in vitro drug combination studies translated in vivo. BT474 cells 
were implanted into the fourth mammary fat pad of athymic 
mice and tumors permitted to grow for 7  days, with initial 
starting tumor volume of ~15 mm3. Nota bene: an established 
15  mm3 tumor volume in the fourth mammary fat pad of 
a 20  g mouse is the equivalent of a 3.7  cm3 tumor volume in 
the breast of a 50-kg female patient. Animals were treated for 
4 days with vehicle control or with (ruxolitinib + afatinib) or 
(ruxolitinib + MMF) [see also (33)]. Treatment of animals with 
ruxolitinib alone or MMF alone did not alter tumor growth 
whatsoever, and treatment of animals with afatinib alone showed 
a trend for reduced BT474 tumor growth that was not statisti-
cally significant (Figure 7B, not shown). A 4-day treatment of 
mice with (ruxolitinib + afatinib) in combination significantly 
reduced the growth of BT474 tumors over a 35-day time course 
(Figure  7B, p  <  0.001). Treatment of animals with (ruxoli-
tinib + MMF) also significantly reduced tumor growth below 
control treated tumors, though to a lesser extent than (ruxoli-
tinib + afatinib) (both, p < 0.05). Thus, the data in Figures 1–7 
validate the combination of (ruxolitinib + ERBB1/2/4 inhibitor) 
and of (ruxolitinib + MMF) as putative anti-cancer therapies for 
mammary tumors (33).
Chaperone proteins regulate the survival of cells through 
multiple mechanisms, and chaperone proteins are often over-
expressed in tumor tissue when compared to matched-normal 
tissues, thus arguing for a therapeutic window between normal 
and tumor tissues for use of chaperone inhibitors (30–32). In 
the recent Booth et  al. manuscript examining multi-kinase 
inhibitors as chaperone inhibitors, we demonstrated that the 
multi-kinase inhibitors sorafenib and pazopanib are potent 
HSP90 and HSP70 ATPase inhibitors, but that neither afatinib 
nor ruxolitinib are direct chaperone ATPase inhibitors (30). 
We discovered that in addition to reducing total HSP90 expres-
sion, (ruxolitinib + afatinib) treatment also rapidly reduced the 
phosphorylation of the HSP90 essential co-chaperone CDC37 
at Serine 13 within 2  h (Figure  8A). (Ruxolitinib +  afatinib) 
treatment reduced total CDC37 expression over a longer 6-h 
FigUre 6 | activated sTaT3, activated aKT, or activated MeK1 protects mammary tumor cells from (ruxolitinib + lapatinib) treatment. (a) SUM149 
and BT474 cells were transfected with either an empty vector plasmid (CMV) or plasmids to express: activated STAT3; activated MEK1; activated AKT; or dominant 
negative IκB S32A S36A. In a portion of the CMV transfected cells, 15 min prior to drug treatment, cells were treated with the JNK inhibitory peptide (JNK-IP, 
10 μM). Twenty-four hours after transfection, cells were treated with vehicle control; or ruxolitinib (1 μM) and lapatinib (1 μM) for 24 h. Twenty-four hours later, cell 
viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification (n = 3 ± SEM). (B) SUM149 cells were transfected with empty 
vector plasmid (CMV) or a plasmid coding for activated STAT3 or a plasmid coding for activated AKT or a plasmid coding for activated MEK1, as indicated. 
Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 6 h after which cells were fixed in place 
and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 10× magnification to detect the total expression and phosphorylation levels of 
the indicated proteins (n = 3 ± SEM) *p < 0.05 lower reduction than vehicle control.
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time course as well as modestly reducing the  co-localization 
of the chaperone HSP90 with CDC37 (Figure  8B; the 
co-localization image has changed from pure yellow with 
vehicle to red-orange after (ruxolitinib +  afatinib) exposure). 
Over-expression of GRP78, HSP70, or HSP90 maintained to 
varying extents the expression of the cyto-protective MCL-1 
and BCL-XL proteins during (ruxolitinib +  afatinib) exposure 
(Figure  8C, p <  0.05). Over-expression of (HSP27 +  GRP78), 
(HSP27 + HSP70), or (HSP70 + HSP90) all protected cells from 
(ruxolitinib +  afatinib) lethality (Figure  8D). Over-expression 
of (HSP70 + HSP90) and of GRP78 prevented the dephospho-
rylation of mTOR and the increased phosphorylation of eIF2α, 
respectively (data not shown). Thus, inactivation of ERK1/2, 
AKT, mTOR, and STAT3 also facilitates cell killing by reduc-
ing the expression of BCL-XL/MCL-1 and well as through the 
decreased protein expression of chaperone proteins that play 
diverse cyto-protective roles.
Based on our multiplex antibody array data as well as 
our immuno-fluorescence data; caspase 3 was being cleaved 
(activated) after drug combination treatment, and we next 
investigated the molecular mechanisms by which (ruxoli-
tinib  +  ERBB1/2/4 inhibitor) was killing tumor cells. Initial 
studies using pharmacologic tools demonstrated that killing 
induced by the (ruxolitinib +  lapatinib) drug combination was 
FigUre 7 | expression of activated sTaT3 prevents the inactivation of aKT and mTOr, and the decline in Bcl-Xl and Mcl-1 expression. 
(a) SUM149 cells were transfected with empty vector plasmid (CMV) or a plasmid coding for activated STAT3 or a plasmid coding for activated AKT or a plasmid 
coding for activated MEK1, as indicated. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] 
for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 10× magnification to detect the total 
expression and phosphorylation levels of the indicated proteins (n = 3 ± SEM). The blue arrows (upwards or downwards) represent statistically significant differences 
in fluorescence intensity. For vector control transfected cells treated with [Rux ± Afat] the comparison is to vector control transfected cells with vehicle treatment. For 
cells transfected with activated constructs and treated with [Rux ± Afat] the comparision is to vector control transfected cells treated with [Rux ± Afat] (all p < 0.05). 
(B) ruxolitinib and afatinib interact in vivo to reduce the growth of mammary carcinoma tumors. Athymic nude mice (~20 g) were injected with 1 × 107 BT474 cells 
into their fourth mammary fat pad (10 animals per treatment group; four groups; a total of 40 mice ± SEM). Tumors were permitted to form for 7 days with tumors at 
that time exhibiting a mean volume of ~15 mm3. A 15 mm3 tumor in a 20 g mouse is the equivalent of a 3.7 cm3 tumor in a 50 kg patient. Athymic mice were treated 
by oral gavage once every day for 4 days: with vehicle (Cremophore); with MMF (50 mg/kg BID); with ruxolitinib (25 mg/kg BID) on days 1–4 and with afatinib 
(25 mg/kg QD) on days 1–4; and in the indicated combinations. After cessation of drug treatment tumors are again calipered and tumor volume was assessed up to 
35 days later (±SEM).
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blocked/reduced by inhibition of: RIP-1 (necroptosis; necrostatin 
1); Vps34 (autophagy; 3-methyl adenine); and caspases (apop-
tosis; zVAD) (data not shown). Inhibition of caspase 8/death 
receptor signaling by over-expression of c-FLIP-s or inhibition 
of caspase signaling downstream of mitochondria by expression 
of dominant negative caspase 9 did not significantly reduce the 
lethality of (ruxolitinib +  lapatinib) treatment (Figure 9A) (34, 
35). This is of note because although the drug combination causes 
pro-caspase 3 cleavage, the actions of this apoptotic enzyme 
are not required to execute the cancer cell. Over-expression of 
BCL-XL or knock down of either BAX or BAK strongly reduced 
drug combination killing (Figures 9A,B). Although knock down 
of PUMA or NOXA was protective against the drug combina-
tion, the effect of either individual knock down on maintaining 
cell viability was less than that of inhibiting both BAX and BAK 
function together.
The toxic BH3 domain protein BID is activated by 
proteolytic cleavage; a cleavage most commonly thought 
to be catalyzed by caspases 8 and 10 downstream of death 
receptors but also less commonly by cathepsin and calpain 
FigUre 8 | (ruxolitinib + afatinib) rapidly reduces cDc37 serine 13 phosphorylation and after 6 h cDc37 total expression. (a,B) SUM149 cells were 
treated with vehicle control or with (ruxolitinib + afatinib) for 2 h or for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-
fluorescence was performed: (a) at 10× magnification to detect the total expression and phosphorylation levels of CDC37 and CDC37 Serine 13, respectively;  
(B) at 60× magnification the total expression of HSP90 and the total expression of CDC37, and the co-localization of the two proteins (n = 3 ± SEM) *p < 0.05 
greater decline than CDC37 protein expression. (c) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, 
or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib 
(1.0 μM)] for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 10× magnification to 
detect the total expression of MCL-1 and BCL-XL (n = 3 ± SEM) *p < 0.05 lower decline than vehicle control. (D) SUM149 cells were transfected with empty vector 
control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were 
treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 24 h. Twenty-four hours later, cell viability was assessed using a live/dead assay in a 
Hermes WiScan microscope at 10× magnification (n = 3 ± SEM) *p < 0.05 greater survival than individual expression of chaperones.
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proteases released due to lysosomal dysfunction/autophagy 
flux (27). While over- expression of c-FLIP-s did not prevent the 
(ruxolitinib  +   lapatinib) drug combination from killing, i.e., 
there is no caspase 8 signaling component being induced; knock 
down of BID very clearly did significantly reduce cell killing 
(Figures  10A,B, p <  0.05). In agreement with there being a 
caspase-independent mechanism for drug combination killing 
also downstream of the mitochondrion, knock down of apoptosis-
inducing factor (AIF) expression reduced cell death; n.b. and, as 
we demonstrated in a prior data set, dominant negative caspase 
9 was not protective (Figures 10B,C).
As non-caspase dependent activation of BID was involved in 
cell killing for the drug combination, and as the drug combina-
tion enhanced Beclin1 expression, and as the proteases usually 
responsible for this biology are stored in the lysosomes, we 
explored whether altered levels of autophagy played any role in 
(ruxolitinib + lapatinib) toxicity. Treatment of cells with (ruxoli-
tinib + lapatinib) increased the numbers of autophagosomes in 
cells in a greater-than-additive fashion and in a time-dependent 
fashion (Figure 11A, p < 0.05). In agreement with our preliminary 
data using 3-methyl adenine, and our ER stress data showing 
increased Beclin1 expression, knock down of Beclin1 or of ATG5 
suppressed, but did not completely abolish, tumor cell killing by 
the (ruxolitinib + lapatinib) drug combination (Figure 11B). In 
agreement with our data showing mTOR dephosphorylation at 
S2448 and S2481, treatment of cells with (ruxolitinib + afatinib) 
decreased the phosphorylation of ULK-1 S757 by >50%, resulting 
in ULK-1 activation as shown by elevated ATG13 S318 phospho-
rylation by >50% which correlated with autophagosome forma-
tion (Figure 12A, p < 0.05). Expression of an activated form of 
mTOR prevented drug-induced phosphorylation of ATG13 S318, 
prevented autophagosome formation, and significantly reduced 
tumor cell killing (Figure 12B, data not shown).
In agreement with our ATG13 S318 phosphorylation and 
activated mTOR viability data, treatment of cells with (ruxoli-
tinib +  lapatinib) caused LC3-GFP intense staining vesicles to 
co-localize with mitochondria (Figure 13A). Treatment of cells 
with (ruxolitinib + lapatinib) also caused LC3-GFP staining vesi-
cles to co-localize with acidic lysosomes (Figure 13B). That is to 
say, we are causing mitophagy and autophagic flux. In agreement 
FigUre 9 | lapatinib and ruxolitinib combine to kill tumor cells through apoptotic, necroptotic, and autophagic pathways (i). (a) SUM149 cells were 
transfected with an empty vector control plasmid (CMV) or plasmids to express: c-FLIP-s; dominant negative caspase 9 or BCL-XL. Twenty-four hours after 
transfection, cells were treated with vehicle control, ruxolitinib (1 μM) and/or lapatinib (1.0 μM). Twenty-four hours later, cell viability was assessed using a live/dead 
assay in a Hermes WiScan microscope at 10× magnification. (B) SUM149 cells were transfected with a scrambled siRNA (siSCR) or siRNA molecules to knock 
down the expression of BAK, BAX, or BAK and BAX together. Twenty-four hours after transfection, cells were treated with vehicle control, ruxolitinib (1 μM) and/or 
lapatinib (1.0 μM). Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification. Lower: 
graphical representation of the data (n = 3 ± SEM) *p < 0.05 less than corresponding value in siSCR cells.
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with the induction of mitophagy, the expression of the mitochon-
drial protein ATADA3 declined 12 h after exposure in parallel to 
increased ATG13 S318 phosphorylation (Figure 13C). We next 
determined whether the induction of autophagosome formation 
was an essential process for activation of BAX and BAK above 
the level of mitochondrial dysfunction or whether it was a conse-
quence downstream of an early form of mitochondrial dysfunc-
tion. Treatment of SUM149 cells with (ruxolitinib +  afatinib) 
activated within 6  h the toxic BH3 domain proteins BAX and 
BAK (Figure 14A). Activation of BAX was almost abolished by 
knock down of Beclin1 or of BID expression, whereas activation 
of BAK was only modestly impacted by BID knock down.
Apoptosis-inducing factor is a mitochondrial protein that is 
released into the cytoplasm upon a lethal stimulus, and it then 
re-locates to the nucleus where it acts to promote a non-caspase 
dependent fragmentation of the DNA. In unstimulated BT474 
cells, AIF co-localized with the mitochondrial protein ATAD3A 
but not with the nuclear protein eIF3A (Figure 14B). Six hours 
after treatment with (ruxolitinib + afatinib), the co-localization 
of AIF with eIF3A in the nucleus had increased and notably 
that ATAD3A levels did not alter suggesting that complete 
destructive mitophagy had not occurred at this time point. 
The chaperone HSP70 can bind to the released AIF protein in 
the cytosol where it inhibits AIF translocation to the nucleus, 
thereby blocking AIF-dependent killing; our prior data in this 
paper had shown chaperone expression, including that of HSP70, 
was being reduced by (ruxolitinib + afatinib). Treatment of cells 
with (ruxolitinib +  afatinib) resulted in reduced expression of 
HSP70 and reduced co-localization of AIF with HSP70 in the 
cytosol (Figure 14C). That is to say, both the ruxolitinib alone and 
afatinib alone treatments caused a translocation of AIF into the 
cytosol where it associated with HSP70 at similar levels based on 
the “pure” yellow fluorescent stain, whereas in cells treated with 
(ruxolitinib + afatinib) the cellular fluorescent stain was a “dirty” 
reddish-yellow. Collectively, these protein co-localization data 
suggest that under these treatment conditions, there was cytosolic 
red fluorescent AIF protein that was not associated with cytosolic 
green fluorescent HSP70.
Finally, with the intention to initiate in the near future a phase I 
dose-limiting toxicity trial combining (ruxolitinib + an ERBB1/2/4 
inhibitor) in patients at Massey Cancer Center, we performed 
additional multiplex antibody array analyses on tumor material 
FigUre 10 | lapatinib and ruxolitinib combine to kill tumor cells through apoptotic, necroptotic, and autophagic pathways (ii). (a) SUM149 cells were 
transfected with a scrambled siRNA (siSCR) or siRNA molecules to knock down the expression of NOXA, PUMA, or NOXA and PUMA together. Twenty-four hours 
after transfection, cells were treated with vehicle control, ruxolitinib (1 μM) and/or lapatinib (1.0 μM). Twenty-four hours later, cell viability was assessed using a live/
dead assay in a Hermes WiScan microscope at 10× magnification. (B) SUM149 cells were transfected with a scrambled siRNA (siSCR) or siRNA molecules to 
knock down the expression of BID or of apoptosis-inducing factor (AIF). Twenty-four hours after transfection, cells were treated with vehicle control, ruxolitinib (1 μM) 
and/or lapatinib (1.0 μM). Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification.  
(c) Graphical representation of the data (n = 3 ± SEM) *p < 0.05 less than corresponding value in siSCR cells.
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from the (ruxolitinib +  afatinib) BT474 tumor growth experi-
ment to identify possible response biomarkers in tumor cells that 
had survived and re-grown after drug treatment. Control-treated 
BT474 tumors and tumors that had survived and re-grown after 
(ruxolitinib + afatinib) therapy were homogenized and processed 
for multiplex assays. The re-grown (ruxolitinib  +  afatinib) 
exposed tumors exhibited significantly higher expression levels of 
the cytokines human IL-8 and human IL-18 (Figure 15A). Similar 
data were observed for human CXCL-1 (not shown). In other 
words, (ruxolitinib +  ERBB1/2/4 inhibitor) treatment initially 
reduces CXCL-1, IL-8, and IL-18 expression that then rebounds 
in the surviving tumor cells, being over-expressed (Figure 15A) cf 
in vitro multiplex data in (Figure 3). Re-grown mammary tumors 
that were exposed to (ruxolitinib + afatinib) also exhibited sig-
nificantly higher levels of phosphorylated p65 NFκB S536, IκB 
S32 S36, c-Jun S63, AKT T308, ERBB1 Y1173/Y1068, VEGFR2 
Y1175, BAD S112, and ERK1/2, and significantly lower levels 
of ERBB2 Y1289, p70 S6K T389 and mTOR S2448 and P-S6 
phosphorylation. The phosphorylation changes in NFκB/IκB 
together argue for activation of NFκB transcriptional signaling in 
the re-grown tumor cells. (Ruxolitinib + afatinib)-treated tumors, 
in agreement with lower levels of mTOR activity, had higher 
basal ATG13 S318 phosphorylation and an elevated basal level of 
autophagosomes (data not shown).
Treatment of BT474 tumor cells in  vitro with (ruxoli-
tinib +  afatinib) increased the expression of the IL-8 receptors 
CXCR1 and CXCR2 on the cell surface (Figure 15B). Combined 
molecular knock down of both of the IL-8 receptors CXCR1 and 
CXCR2 modestly though significantly enhanced the lethality of 
(ruxolitinib +  afatinib) treatment in both BT474 and SUM149 
cells (p < 0.05). This suggests that CXCR1 and CXCR2 signaling 
provides the surviving re-grown tumor cells with a paracrine loop 
from IL-8 and CXCL-1 to maintain tumor cell survival. Whether 
this also alters immune cell infiltration into the tumor and, thus, 
tumor sensitivity to checkpoint inhibitors will require detailed 
additional studies.
Collectively, our data argue that after (ruxolitinib + afatinib) 
drug combination exposure, an ERBB1-(ERK  +  AKT)-NFκB 
FigUre 11 | lapatinib and ruxolitinib interact to stimulate autophagosome formation. (a) SUM149 cells were transfected with a plasmid to express 
LC3-GFP. Twenty-four hours after transfection, cells were treated with vehicle control, lapatinib (1 μM), ruxolitinib (1 μM), or in combination as indicated for 6 h or for 
12 h. At each time point, cells were visualized using a fluorescent microscope at 40× magnification, and the mean number of intense punctate GFP-positive vesicles 
per cell determined in >40 cells from random fields ± SEM (*p < 0.05 greater than lapatinib alone or ruxolitinib alone treatments). (B) SUM149 cells were transfected 
with a scrambled siRNA (siSCR) or siRNA molecules to knock down the expression of Beclin1 or of ATG5. Twenty-four hours after transfection, cells were treated 
with vehicle control, ruxolitinib (1 μM), and/or lapatinib (1.0 μM). Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan 
microscope at 10× magnification (n = 3 ± SEM) *p < 0.05 less than corresponding value in siSCR cells.
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pathway becomes activated in surviving BT474 cells to promote 
“recurrent” tumor growth; as BAD S112 phosphorylation is 
increased, this pathway also likely acts to reduce the apoptotic 
threshold by inactivating BAD. Studies beyond the scope of the 
present manuscript and our data with IL-8 receptor and IL-18 
receptor signaling will be required to prove whether this signaling 
“fingerprint” in the re-grown tumors can be used as a template for 
designing new anti-tumor drug combinations.
DiscUssiOn
The present studies were undertaken to determine whether the 
myelo-proliferative disorder medication ruxolitinib (Jakafi®) 
could be repurposed as a solid tumor cancer therapeutic. We 
discovered that ruxolitinib at clinically relevant free drug con-
centrations synergized with multiple ERBB1/2/4 inhibitors to 
kill tumor cells, including those expressing mutated active RAS 
proteins or lacking the tumor suppressor PTEN. Unlike the drugs 
OSU-03012 (AR12), sorafenib or pazopanib, neither afatinib nor 
ruxolitinib inhibited the ATPase activities of cyto-protective 
chaperone proteins but instead, in combination, reduced the 
protein expression of the HSP90 and HSP70 chaperones (30–32). 
That the protein expression of both HSP90 and HSP70 were 
reduced argues that our drug combination may utilize multiple 
pathways in any given tumor cell to cause cell death, explaining 
why cells that expressed activated oncogenes, such as RAS, or 
had inactivated tumor suppressor genes, such as PTEN, were all 
drug-combination sensitive.
Tumor cell killing by (ruxolitinib +  ERBB inhibitor) treat-
ment occurred in a wide variety of tumor cell types, including 
many genetically diverse PDX models of GBM and lung cancer. 
Multiple first-, second-, and third-generation ERBB1/2/4 inhibi-
tors could interact with ruxolitinib to kill tumor cells. Knock 
down of ERBB1/2/3/4 protein expression in the three tumor cell 
isolates we examined recapitulated the toxic interaction of the 
ERBB1/2/4 inhibitors with ruxolitinib. Similarly, we noted that 
combined knock down of JAK1 and JAK2 could recapitulate the 
FigUre 12 | lapatinib/afatinib and ruxolitinib kill tumor cells through toxic mitophagy. (a) BT474 cells were transfected with empty vector plasmid (CMV) 
or a plasmid coding for activated mTOR. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1 μM) + afatinib (1 μM)] for 
6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the total expression and 
phosphorylation levels of the indicated proteins. (B) SUM149 and BT474 cells were transfected with empty vector plasmid (CMV) or a plasmid coding for activated 
mTOR. Twenty-four hours after transfection, cells were treated with vehicle control, ruxolitinib (1 μM) and afatinib (1.0 μM). Twenty-four hours later, cell viability was 
assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification (n = 3 ± SEM) *p < 0.05 less than corresponding value in CMV cells.
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FigUre 13 | ruxolitinib and lapatinib interact to stimulate mitophagy. (a) SUM149 cells were transfected with a plasmid to express LC3-GFP. Twenty-four 
hours after transfection, cells were treated with vehicle control, lapatinib (1 μM), ruxolitinib (1 μM), or in combination as indicated for 6 h. Cells were then treated with 
mito-tracker red (100 nM) for 15 min. Cells were rapidly visualized using a fluorescent microscope at 40× magnification in the red and green fluorescent channels. 
The red and green images were merged in Adobe Photoshop CS6; areas of yellow staining indicate the co-localization of GFP and mito-tracker red staining.  
(B) SUM149 cells were transfected with a plasmid to express LC3-GFP. Twenty-four hours after transfection, cells were treated with vehicle control, lapatinib (1 μM), 
ruxolitinib (1 μM), or in combination as indicated for 12 h. Cells were then treated with lyso-tracker red (100 nM) for 15 min. Cells were rapidly visualized using a 
fluorescent microscope at 40× magnification in the red and green fluorescent channels. The red and green images were merged in Adobe Photoshop CS6; areas of 
yellow staining indicate the co-localization of GFP and lyso-tracker red staining. (c) SUM149 cells were treated with vehicle control or with [ruxolitinib 
(1 μM) + afatinib (0.5 μM)] for 12 h, after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect 
the expression of ATAD3A and ATG13 S318 with images at 60× magnification.
16
Tavallai et al. Ruxolitinib and Cancer Therapy
Frontiers in Oncology | www.frontiersin.org June 2016 | Volume 6 | Article 142
toxic effects of ruxolitinib in a cell type-dependent fashion when 
combined with ERBB1/2/4 inhibitors. There is another Janus 
kinase inhibitor that is approved by the FDA, for the treatment 
of rheumatoid arthritis, tofacitinib (Xeljanz®). Tofacitinib is a 
JAK3 inhibitor and demonstrates some JAK1 pathway inhibitory 
effects in mouse models of arthritis. In contrast to ruxolitinib, 
tofacitinib did not consistently enhance the lethality of lapatinib 
or of MMF in our four PDX GBM isolates [(33, Tavallai and Dent, 
Unpublished Observations1)]. Tofacitinib enhanced lapatinib 
toxicity and MMF toxicity only in GBM6 and GBM14 cells, but 
not in GBM5 or GBM12 cells. To Dent laboratory investiga-
tors such findings are conceptually important because as we 
experienced with our in depth analyses of OSU-03012 (AR12) 
biology, originally proposed to be an inhibitor of PDK-1 in the 
PI3K pathway, only by rational unbiased experimental studies did 
we eventually determine that the OSU-03012 drug is in fact a 
1In preliminary studies we discovered that the drug combina tion reduced BAD 
S112 phosphorylation by ~50% and that knock down of BAD reduced the lethality 
of (ruxoli tinib + afatinib) and also reduced drug-induced activation of the toxic 
BH3 domain protein BAX. Methods used were identical to those in published 
Figures in the manuscript. 
potent inhibitor of multiple cyto-protective chaperone proteins, 
including GRP78, HSP90, and HSP70 (30).
In both BT474 and in SUM149 mammary carcinoma cells, 
expression of constitutively active STAT3; or of activated 
AKT; or of activated MEK1 were shown to be a key individual 
protective molecular signals to suppress (ruxolitinib  +  ERBB 
inhibitor) – induced killing, though of additional note molecular 
inhibition of JNK pathway signaling could also reduce the death 
response. In part, activated STAT3/activated AKT/activated 
MEK as individual signals could partially protect tumor cells 
because each activated protein maintained to varying degrees: (a) 
the expression of the mitochondrial and endoplasmic reticulum 
protective proteins BCL-XL and MCL-1; (b) suppressed activa-
tion of the endoplasmic reticulum stress eIF2α-Beclin1 pathway; 
(c) and stabilized the levels of cyto-protective chaperone proteins, 
proteins whose essential pleiotropic cyto-protective effects on 
many signaling and cell death pathway targets will collectively 
collaborate to prevent drug-induced tumor cell killing (30–32).
The killing mechanisms induced by the (ruxolitinib + ERBB 
inhibitor) treatment were many-fold, most notably that 
(ruxolitinib +  ERBB inhibitor) treatment caused a significant 
greater-than-additive increase in the levels of autophagosome 
FigUre 14 | activation of BaX and BaK requires the initial induction of autophagy. (a) SUM149 cells were transfected with a scrambled nonsense siRNA 
molecule (SCR), or siRNA molecules to knock down the expression of BID or of Beclin1. Twenty-four hours after transfection, cells were treated for 6 h with vehicle 
control (VEH) or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM) for 6 h. Immuno-precipitates of active BAX and of active BAK are run on SDS-PAGE (14%) and 
electrophoresed proteins transferred to 0.22-μm-thick nitrocellulose membranes for immunoblotting against the total expression of BAX and of BAK under each 
condition. (B) SUM149 cells were treated with vehicle control or with [ruxolitinib (1 μM) and/or afatinib (1.0 μM)] as indicated for 6 h after which cells were fixed in 
place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 60× magnification to detect the co-localization levels of the indicated 
proteins, and for the total expression level of AIF. (c) SUM149 cells were treated with vehicle control or with [ruxolitinib (1 μM) and/or afatinib (1.0 μM)] for 6 h after 
which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 60× magnification to detect the co-localization 
levels of the indicated proteins, and the expression of HSP70 using a COOH terminal epitope antibody.
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formation that was associated with mitochondrial degradation 
and activation of caspase 3; as well as autolysosome formation, 
mitochondrial degradation, AIF translocation to the nucleus, 
and a necroptotic form of tumor cell death. Our studies strongly 
argued that the rapid inactivation of the PI3K–mTOR pathway 
caused by direct kinase inhibition and by subsequent reduced 
chaperone protein expression in parallel with increased PERK-
eIF2α ER stress signaling leading to elevated Beclin1 levels 
were the key upstream pathways by which tumor cell death was 
being triggered. The confluence of these signaling events was 
the increase in autophagosome formation; autophagosomes 
that co-localized with mitochondria (mitophagy) and then with 
lysosomes (autolysosomes). Activation of the executioner toxic 
BH3 domain proteins BAX and BAK required increased Beclin1 
expression (autophagosome formation) and also the activation/
cleavage of BID due to the release into the cytosol of cathepsins 
and calpains (autolysosome disintegration).
One chaperone-associated protein that plays a key survival 
regulatory role downstream of the mitochondrion, and that we 
validated in our drug-combination system as a probable chap-
erone effector for cell killing, as has been observed by others, 
is AIF. The chaperone HSP70, often over-expressed in tumors, 
can sequester and inactivate cytosolic AIF previously released 
from the mitochondrion, thereby preventing AIF translocating 
to the nucleus where it would trigger tumor cell death. That our 
drug combination: (a) reduced HSP70: AIF co-localization in 
the cytosol; (b) increased eIF3A: AIF association in the nucleus; 
and (c) reduced total HSP70 expression, strongly argues that 
the upstream mTOR inhibition/ER stress-autophagy-BAX/
BAK/BID-dependent AIF release from the mitochondria and 
the facilitation of its translocation to the nucleus is very likely 
the key mechanism by which our (ruxolitinib +  afatinib) drug 
combination was killing tumor cells.
One additional commonality in our studies exploring the 
molecular mechanisms by which (ruxolitinib + ERBB inhibitors) 
killed tumor cells, based on our siRNA analyses of ERBB family 
receptors, was the importance of signaling through ERBB3, a 
receptor lacking tyrosine kinase activity but containing six sites 
FigUre 15 | Multiplex antibody array assays demonstrate that tumors previously exposed to (ruxolitinib + afatinib) exhibit elevated expression of 
il-8 and il-18. (a) Tumor material, isolated at day 35, was homogenized and prepared for the multiplex assays as under the manufacturer’s instructions. Multiplex 
assays were performed in a Bio-Rad MAGPIX machine using the multiplex plates as discussed in the section “Methods.” Data are presented as the mean of five 
separate control and (ruxolitinib + afatinib) tumors (± SD). *p < 0.05 greater than control value; #p < 0.05 less than control value. (B) left. BT474 tumor cells in vitro 
were treated with vehicle control or [ruxolitinib (2 μM) + afatinib (2 μM)] for 6 h. After 6 h cells were fixed in place without being permeabilized. Immuno-fluorescence 
was performed to detect the cell surface expression of the IL-8 receptor (right). BT474 cells and SUM149 cells were transfected with a scrambled siRNA or a siRNA 
to knock down expression of the IL-8 receptor. Twenty-four hours after transfection, cells are treated with vehicle control or [ruxolitinib (2 μM) + afatinib (2 μM)] for 
24 h. Cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification.
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